DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 3570--------------------------------------------------
       (ACTRIMS) PML incidence rates in US patients treated w/natalizum
       ab
       By: agate Date: March 1, 2022, 1:03 am
       ---------------------------------------------------------
       Abstract of a poster presentation at the annual ACTRIMS
       conference held in West Palm Beach, FL, February 24-26,
       2022--"PML incidence rates in US patients treated with
       natalizumab: Update from the TOUCH program":
  HTML https://www.abstractsonline.com/pp8/#!/10495/presentation/255
       It has been difficult to find data on the Tysabri-related PML
       cases.  The authors of this presentation are employees of
       Biogen, a fact that raises the suspicion that the data might be
       skewed in favor of Tysabri, but at least they are presenting
       some figures.
       *****************************************************